ArticleScience advances2023
Enhanced
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in Science advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 28 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
7.8field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Antisense Versus Antigene in the Computer-Aided Design of Triplex-Forming Oligonucleotides (TFO): Insights from a Dual-Method Review, Combining Bibliometric and Systematic Review.International journal of molecular sciences · 2025Pooled it
- The Natural Quassinoid Brusatol Enhances Venetoclax Efficacy and Overcomes Resistance in Myeloid Leukemias.Cancer science · 2026Article
- MYC in Oncogenesis and Therapeutic Implications.MedComm · 2026Review
- Oncogene c‑Myc: From molecular mechanism to targeted therapy (Review).Molecular medicine reports · 2026Review
- HDAC8 inhibition targets STAT3-MYC axis and synergizes with Venetoclax in KMT2A-rearranged acute myeloid leukemia.Leukemia · 2026Article
- Inhibition of ADSS2-mediated de novo AMP biosynthesis re-sensitizes acute myeloid leukemia to BH3 mimetics.Nature cancer · 2026Article
- Targeting the nuclear export receptor exportin-1 in acute myeloid leukaemia: From biology to clinical translation.Clinical and translational medicine · 2026Review
- Evolution of Engineered ADAR-Based RNA Editing Systems.International journal of molecular sciences · 2026Review
- Myeloid sarcoma transformed from myeloproliferative neoplasm: A case report and review of literature.World journal of clinical oncology · 2026Article
- Liquiritin restores metabolic homeostasis in NAFLD by modulating AKT1/FOXO1 signaling.Frontiers in pharmacology · 2026Article
- Co-activation of the super-enhancer complex SOX2 and HDAC1 confers temozolomide resistance by promoting PDGFB transcription in glioblastoma.Neuro-oncology · 2026Article
- Gastrointestinal cancer: molecular pathogenesis and targeted therapy.Molecular biomedicine · 2025Review
- Article
- Targeting the Liquid-Liquid Separation Region of c-Maf for Treating Chromosomal Translocations in Multiple Myeloma.MedComm · 2025Article
- Cooperative role of distinctive TP53 and PTEN combined loss in the peripheral T cell lymphoma-GATA3 molecular subgroup.Science advances · 2025Article
- Targeting the BCL2 Family: Advances and Challenges in BH3 Mimetic-Based Therapies.International journal of molecular sciences · 2025Review
- Article
- Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild-type Acute Myeloid Leukemias.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Genetic modeling of ELP1-associated Sonic hedgehog medulloblastoma identifies MDM2 as a selective therapeutic target.Cancer cell · 2025Article
- Venetoclax synergizes with Wnt/β-catenin inhibitor C-82 in acute myeloid leukemia by increasing the degradation of Mcl-1 protein.Cancer cell international · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
20 authors at 4 institutions in 4 countries.
Yuki NishidaSection of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-5827-7406
Jo IshizawaSection of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-8566-7370
Edward AyoubSection of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0003-1321-0114
Rafael Heinz MontoyaSection of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0003-2335-5894
Lauren B OstermannSection of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-3330-2174
Muharrem MuftuogluSection of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-8100-8554
Vivian R RuvoloSection of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0003-4363-7258
Tallie PatsilevasSection of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Darah A ScruggsSection of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Shayaun KhazaeiSection of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0009-0004-2677-8176
Po Yee MakSection of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Wenjing TaoSection of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Bing Z CarterSection of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0003-0076-0889
Steffen BoettcherDepartment of Medical Oncology and Haematology, University Hospital Zurich, University of Zurich, Zurich 8091, Switzerland.ORCID 0000-0001-9937-0957
Benjamin L EbertBrigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, The Broad Institute, Boston, MA 02115, USA.ORCID 0000-0003-0197-5451
Naval G DaverDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-7103-373X
Marina KonoplevaDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Takahiko SekiDaiichi Sankyo Co. Ltd., Tokyo 103-8426, Japan.
Kensuke KojimaSection of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0003-4138-0604
Michael AndreeffSection of Molecular Hematology and Therapy, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-1144-1958
The University of Texas MD Anderson Cancer Center · USDaiichi Sankyo (Germany) · DEDana-Farber Cancer Institute · USUniversity Hospital of Zurich · CH
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MUniversity of Texas M.D. Anderson Cancer SPORE-LeukemiaP50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHPALL, ELIZABETH J · 2003 to 2023
$43.7MTherapeutic targeting of p53 reactivation-induced OXPHOS dependency and stress responses to overcome resistance to venetoclax/HMA in AMLR21CA267401 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ANDREEFF, MICHAEL · 2022 to 2023
$412kTargeting Quiescence Pathways to Overcome Chemoresistance in EVI1-Overexpressing LeukemiaF32CA271697 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AYOUB, EDWARD · 2022 to 2024
$226kNCI NIH HHS F32 CA271697NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA100632NCI NIH HHS R21 CA267401
Abstract
The tumor suppressor
Indexed as
Leukemia, Myeloid, AcuteTumor Suppressor Protein p53ApoptosisBridged Bicyclo Compounds, HeterocyclicCell Line, TumorHumansProto-Oncogene Proteins c-mdm2SulfonamidesBridged Bicyclo Compounds, HeterocyclicProto-Oncogene Proteins c-mdm2SulfonamidesTP53 protein, humanTumor Suppressor Protein p53venetoclax
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.